Buy Rating Affirmed for Biomea Fusion with Promising BMF-219 Clinical and Regulatory Developments
Joseph Pantginis, an analyst from H.C. Wainwright, maintained the Buy rating on Biomea Fusion (BMEA – Research Report). The associated ...
Piper Sandler Remains a Buy on Biomea Fusion (BMEA)
In a report released today, Joseph Catanzaro from Piper Sandler maintained a Buy rating on Biomea Fusion (BMEA – Research Report), with a ...
Absence of Black Box Warning For Bristol Myers' Schizophrenia Treatment Could Enhance Alzheimer's Psychosis Potential
Bristol Myers' Cobenfy, recently approved by the FDA for schizophrenia, lacks a boxed warning, positioning it as a safer ...
Biomea upgraded by analysts after FDA lifts clinical hold
Biomea (BMEA) has received two analyst upgrades along with bullish comments from other firms following news the FDA has lifted a clinical hold on a study of its drug BMF-219.
FDA Removes Clinical Hold On Biomea Fusion's Early-Stage Trials For Potential Diabetes Candidate
Friday, the FDA lifted the clinical hold on Biomea Fusion, Inc.’s (NASDAQ:BMEA) ongoing Phase 1/2 clinical trials of the ...
Biomea’s stock bounces back as FDA lifts clinical hold on diabetes trials
The US FDA placed a full clinical hold on two diabetes trials for Biomea’s menin inhibitor after reports of liver toxicity.
IonQ, Biomea Fusion, Rocket Lab USA And Other Big Stocks Moving Higher On Friday
Biomea Fusion, Inc. BMEA shares jumped 15.5% to $11.05. Biomea Fusion disclosed that the FDA lifted its clinical hold on ...
devdiscourse7h
Major Developments in Health Sector: New Drugs and Global Initiatives
The U.S. FDA approved Bristol Myers' new schizophrenia drug, the first of its kind in decades. Bavarian Nordic signed an ...
bovnews9h
The Biomea Fusion Inc Stock Thriller: Decoding the Mystery Behind BMEA’s Recent Movements
On Thursday, Biomea Fusion Inc (BMEA) stock saw a modest uptick, ending the day at $9.57 which represents a slight increase of $0.80 or 9.12% from the prior close of $8.77. The stock opened at $8.98 ...
FierceBiotech10h
FDA lifts hold on diabetes trials after Biomea mitigates liver toxicity risk
Biomea Fusion has escaped from the full clinical hold imposed by the FDA. | Biomea Fusion has escaped from the full clinical hold imposed by the FDA. After reviewing the data, the regulator has ...
Biomea Fusion, Inc.: FDA Lifts Clinical Hold on BMF-219 in Type 2 and Type 1 Diabetes Trials
Biomea Fusion, Inc. ("Biomea" or the "Company") (Nasdaq: BMEA), a clinical-stage biopharmaceutical company dedicated to discovering and developing ...
FDA Lifts Clinical Hold on BMF-219 in Type 2 and Type 1 Diabetes Trials
REDWOOD CITY, Calif., Sept. 26, 2024 (GLOBE NEWSWIRE) -- (“Biomea” or the “Company”) (Nasdaq: BMEA), a clinical-stage biopharmaceutical company dedicated to discovering and developing oral covalent ...